Follow
Peter Houghton
Peter Houghton
Unknown affiliation
Verified email at uthscsa.edu
Title
Cited by
Cited by
Year
The TOR pathway: a target for cancer therapy
MA Bjornsti, PJ Houghton
Nature Reviews Cancer 4 (5), 335-348, 2004
16802004
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin
GJ Brunn, CC Hudson, A Sekulic, JM Williams, H Hosoi, PJ Houghton, ...
Science 277 (5322), 99-101, 1997
12211997
mTOR and cancer therapy
JB Easton, PJ Houghton
Oncogene 25 (48), 6436-6446, 2006
6182006
Targeting mTOR signaling for cancer therapy
S Huang, PJ Houghton
Current opinion in pharmacology 3 (4), 371-377, 2003
6032003
Establishment of human tumor xenografts in immunodeficient mice
CL Morton, PJ Houghton
Nature protocols 2 (2), 247-250, 2007
5762007
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations
WT Beck, TM Grogan, CL Willman, C Cordon-Cardo, DM Parham, ...
Cancer research 56 (13), 3010-3020, 1996
5061996
The pediatric preclinical testing program: description of models and early testing results
PJ Houghton, CL Morton, C Tucker, D Payne, E Favours, C Cole, ...
Pediatric blood & cancer 49 (7), 928-940, 2007
4972007
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
PJ Houghton, PJ Cheshire, JD Hallman, L Lutz, HS Friedman, MK Danks, ...
Cancer chemotherapy and pharmacology 36 (5), 393-403, 1995
4261995
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro
PJ Houghton, GS Germain, FC Harwood, JD Schuetz, CF Stewart, ...
Cancer research 64 (7), 2333-2337, 2004
4232004
Rapamycins: mechanisms of action and cellular resistance
S Huang, MA Bjornsti, PJ Houghton
Cancer biology & therapy 2 (3), 222-232, 2003
4212003
Irinotecan therapy in adults with recurrent or progressive malignant glioma
HS Friedman, WP Petros, AH Friedman, LJ Schaaf, T Kerby, J Lawyer, ...
Journal of Clinical Oncology 17 (5), 1516-1516, 1999
4181999
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ...
Nature medicine 25 (12), 1938-1947, 2019
3972019
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells
H Hosoi, MB Dilling, T Shikata, LN Liu, L Shu, RA Ashmun, GS Germain, ...
Cancer research 59 (4), 886-894, 1999
3891999
A specific chromosomal abnormality in rhabdomyosarcoma
EC Douglass, M Valentine, E Etcubanas, D Parham, BL Webber, ...
Cytogenetic and Genome Research 45 (3-4), 148-155, 1987
3751987
Potentiation of neuroblastoma metastasis by loss of caspase-8
DG Stupack, T Teitz, MD Potter, D Mikolon, PJ Houghton, VJ Kidd, ...
Nature 439 (7072), 95-99, 2006
3432006
mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α
H Cam, JB Easton, A High, PJ Houghton
Molecular cell 40 (4), 509-520, 2010
3182010
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition
L Dudkin, MB Dilling, PJ Cheshire, FC Harwood, M Hollingshead, ...
Clinical Cancer Research 7 (6), 1758-1764, 2001
3162001
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors
OM El-Badry, C Minniti, EC Kohn, PJ Houghton, WH Daughaday, ...
Cell Growth Differ 1 (7), 325-331, 1990
3151990
RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis
HK Bid, RD Roberts, PK Manchanda, PJ Houghton
Molecular cancer therapeutics 12 (10), 1925-1934, 2013
2962013
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors
PJ Houghton, PJ Cheshire, L Myers, CF Stewart, TW Synold, ...
Cancer chemotherapy and pharmacology 31 (3), 229-239, 1992
2851992
The system can't perform the operation now. Try again later.
Articles 1–20